Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00267930 · ClinicalTrials.gov registry record · Phase 2

Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence

A Phase 2 study of Atrial Fibrillation, sponsored by Advanz Pharma.

Completed
Registry status
Phase 2
Development phase
221
Enrollment target
20
Study locations

NCT00267930 is a Phase 2 study of Atrial Fibrillation that has completed, run by Advanz Pharma. The registered enrollment target is 221 participants, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00267930, a Phase 2 study of Atrial Fibrillation, has completed, sponsored by Advanz Pharma.

COMPLETED
Registry status
Phase 2
Development phase
221 participants
Enrollment target
20
Study locations

Study Summary

This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

Conditions Studied

Atrial Fibrillation

Interventions

  • DRUG Placebo comparator
  • DRUG Vernakalant (oral)

Study Locations (20)

Other

  • Aalborg Sygehus Syd - Aalborg
  • Aarhus Sygehus Kardiologisk Afd. A - Aarhus
  • Bispebjerg Hospital - Copenhagen
  • Kardiologisk/endokrinologisk afd. E Frederiksberg Hospital - Frederiksberg
  • KAS Gentofte Kardiologisk Afdeling - Hellerup
  • KAS Herlev - Herlev
  • Sygehus Vendsyssel Hjorring - Hjørring
  • Medicinsk Afdeling Kolding Sygehus - Kolding
  • Roskilde Amts Sygehus Koge - Køge
  • Reinier de Graaf Gasthuis - Delft
  • Catharina Ziekenhuis - Eindhoven
  • Medisch Spectrum Twente - Enschede
  • University Medical Center Groningen (UMCG) - Groningen
  • Trial sectie Cardiologie - Heerlen

Alabama

  • The Heart Center, P.C. - Huntsville

California

  • Cardiovascular Consultants Medical Group, Inc. - Walnut Creek

Pennsylvania

  • Penn State Heart & Vascular Institute - Hershey

Wisconsin

  • Marshfield Clinic - Marshfield

Alberta

  • Foothills Hospital - Calgary

Quebec

  • Centre Hospitalier de l'Université de Montréal (CHUM) Hôtel Dieu - Montreal

Trial Details

FieldValue
Enrollment Target 221 participants
Start Date 2005-12
Est. Completion 2006-08
Phase Phase 2

Sponsor

Advanz Pharma

4 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00267930

The ClinicalTrials.gov registry entry for NCT00267930 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 221 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,996-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (93% lower). The listed sponsor is Advanz Pharma, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Placebo comparator is the first listed.

NCT00267930 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, Alabama, California.

Frequently Asked Questions

What is clinical trial NCT00267930 about?

NCT00267930 is a clinical study titled "Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence". This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration

What is the current status of trial NCT00267930?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 221 participants. The study started on 2005-12. Estimated completion is 2006-08.

What conditions does trial NCT00267930 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT00267930?

The interventions under investigation include: Placebo comparator (DRUG), Vernakalant (oral) (DRUG).

Who is sponsoring clinical trial NCT00267930?

This trial is sponsored by Advanz Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00267930 being conducted?

This trial has 20 study locations across Alabama, California, Pennsylvania, Wisconsin, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Atrial Fibrillation

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.